中文名稱(chēng)：兔抗EIF4G1 (phospho-Ser1232)多克隆抗體

英文名稱(chēng)： Anti-EIF4G1 (phospho-Ser1232) rabbit polyclonal antibody

別名： P220; EIF4F; EIF4G; EIF4GI; PARK18; EIF-4G1

相關(guān)類(lèi)別： 一抗

儲(chǔ) 存： 冷凍（-20℃）避光

宿主： Rabbit

抗原： EIF4G1 (phospho-Ser1232)

反應(yīng)種屬： Human

標(biāo) 記物： Unconjugate

克隆類(lèi)型： rabbit polyclonal

技術(shù)規(guī)格

Background:

eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis

Applications:

WB, IHC

Name of antibody:

EIF4G1 (phospho-Ser1232)

Immunogen:

Synthetic peptide of human EIF4G1 (phospho-Ser1232)

Full name:

eukaryotic translation initiation factor 4 gamma, 1 (phospho-Ser1232)

Synonyms：

P220; EIF4F; EIF4G; EIF4GI; PARK18; EIF-4G1

SwissProt:

G5E9S1

IHC positive control:

Human lung carcinoma

IHC Recommend dilution:

50-100

WB Predicted band size:

220 kDa

WB Positive control:

HT29 cells treated with Anisomycin

WB Recommended dilution:

500-1000

展開(kāi)全部

兔抗EIF4G1 (phospho-Ser1232)多克隆抗體說(shuō)明書(shū)
下載

久久综合九九-久久综合九九亚洲一区-久久综合九色-久久综合九色欧美综合狠狠-久久综合九色婷婷97-久久综合九色综合8888

021-54845833/15800441009

ELISA試劑盒

PCR試劑盒

生化試劑盒

細(xì)胞系

細(xì)胞庫(kù)

基礎(chǔ)培養(yǎng)基

完全培養(yǎng)基

原代細(xì)胞

細(xì)胞專(zhuān)用培養(yǎng)基

菌株

生化試劑

病理染色液

科研抗體

標(biāo)準(zhǔn)品

血清

形態(tài)病理檢測(cè)

分子病理

超微病理

產(chǎn)品中心

最新產(chǎn)品

相關(guān)文章

兔抗EIF4G1 (phospho-Ser1232)多克隆抗體

Background:	eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis
Applications:	WB, IHC
Name of antibody:	EIF4G1 (phospho-Ser1232)
Immunogen:	Synthetic peptide of human EIF4G1 (phospho-Ser1232)
Full name:	eukaryotic translation initiation factor 4 gamma, 1 (phospho-Ser1232)
Synonyms：	P220; EIF4F; EIF4G; EIF4GI; PARK18; EIF-4G1
SwissProt:	G5E9S1
IHC positive control:	Human lung carcinoma
IHC Recommend dilution:	50-100
WB Predicted band size:	220 kDa
WB Positive control:	HT29 cells treated with Anisomycin
WB Recommended dilution:	500-1000